Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Nahomi, Tokudome"'
Autor:
Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, Koichi Sato, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Hiroaki Akamatsu, Yuichi Ozawa, Keiichiro Akamatsu, Katsuya Endo, Masayuki Higuchi, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto
Publikováno v:
Cancer Medicine, Vol 9, Iss 6, Pp 2122-2133 (2020)
Abstract Noninvasive diagnostics using circulating tumor cells (CTCs) are expected to be useful for decision making in precision cancer therapy. AXL, a receptor tyrosine kinase is associated with tumor progression, epithelial‐to‐mesenchymal trans
Externí odkaz:
https://doaj.org/article/93df0d4a0bea451c9197d68d6d5d0747
Autor:
Nahomi Tokudome, Yasuhiro Koh, Hiroaki Akamatsu, Daichi Fujimoto, Isamu Okamoto, Kazuhiko Nakagawa, Toyoaki Hida, Fumio Imamura, Satoshi Morita, Nobuyuki Yamamoto
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Epidermal growth factor receptor (EGFR)-sensitizing mutation, exon 19 deletion consists of several molecular variants. Influences of these variants on clinical response to EGFR tyrosine kinase inhibitors remain elusive. Methods We
Externí odkaz:
https://doaj.org/article/b60fdaae47f44203886f8b43ab41f084
Autor:
Daniel F. Hayes, David A. Chianese, Mark C. Connelly, James M. Rae, N. Lynn Henry, Anne F. Schott, Dorothy L. Blossom, M. Craig Miller, Kimberly Aung, Martha E. Brown, Nahomi Tokudome, Kelley M. Kidwell, Kent A. Griffith, Dafydd G. Thomas, Maria C. Muñiz, Costanza Paoletti
Background: Endocrine therapy (ET) fails to induce a response in one half of patients with hormone receptor (HR)–positive metastatic breast cancer (MBC), and almost all will eventually become refractory to ET. Circulating tumor cells (CTC) are asso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aadf3ff396caa8046785d07ed87e779
https://doi.org/10.1158/1078-0432.c.6524091.v1
https://doi.org/10.1158/1078-0432.c.6524091.v1
Autor:
Scott A. Tomlins, James M. Rae, Daniel F. Hayes, Ben H. Park, Michael D. Johnson, Farideh Z. Bischoff, Arul M. Chinnaiyan, Dan R. Robinson, Robert Lonigro, Yi-Mi Wu, Anne F. Schott, Christina Gersch, Dafydd G. Thomas, Nahomi Tokudome, Valeria Sero, Allen R. Blevins, Maryam Yazdani, David Chu, Chia-Jen Liu, Paul J. Baratta, Emily M. Cannell, Elizabeth P. Darga, Kimberly Aung, Daniel H. Hovelson, Jose M. Larios, Andi K. Cani, Costanza Paoletti
Addressing drug resistance is a core challenge in cancer research, but the degree of heterogeneity in resistance mechanisms in cancer is unclear. In this study, we conducted next-generation sequencing (NGS) of circulating tumor cells (CTC) from patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3a18b5cd5f96f693020b929a06018a2
https://doi.org/10.1158/0008-5472.c.6510609.v1
https://doi.org/10.1158/0008-5472.c.6510609.v1
Autor:
Daniel F. Hayes, David A. Chianese, Mark C. Connelly, James M. Rae, N. Lynn Henry, Anne F. Schott, Dorothy L. Blossom, M. Craig Miller, Kimberly Aung, Martha E. Brown, Nahomi Tokudome, Kelley M. Kidwell, Kent A. Griffith, Dafydd G. Thomas, Maria C. Muñiz, Costanza Paoletti
Table S1. Antibodies used for CTC and tissue studies. Table S2. Stage 2 stopping rules for the cumulative number of successfully assayed patients. Table S3. A. CTC-Enumeration Points based on CTC Enumeration B. CTC-Bio-Pointsa Footnotes:aOnly aliquot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c0a31083669e29babf1577e42bdba37
https://doi.org/10.1158/1078-0432.22458948
https://doi.org/10.1158/1078-0432.22458948
Autor:
Daniel F. Hayes, David A. Chianese, Mark C. Connelly, James M. Rae, N. Lynn Henry, Anne F. Schott, Dorothy L. Blossom, M. Craig Miller, Kimberly Aung, Martha E. Brown, Nahomi Tokudome, Kelley M. Kidwell, Kent A. Griffith, Dafydd G. Thomas, Maria C. Muñiz, Costanza Paoletti
Supplementary Figures. Figure S1. Clinical trial study design. Figure S2. Examples of biomarker staining of cultured human breast cancer cell lines after spike and capture from normal human blood using the CellSearch® system. A semi-quantitative sca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86aca4842a09901df75920f502fd5061
https://doi.org/10.1158/1078-0432.22458951
https://doi.org/10.1158/1078-0432.22458951
Autor:
Ben Ho Park, James M. Rae, Daniel F. Hayes, Paula J. Hurley, Josh Lauring, Karen S. Jacks, Dan Robinson, Anne Schott, Arul M. Chinnaiyan, Nahomi Tokudome, Kimberly Aung, Arielle Medford, Riaz Gillani, W. Brian Dalton, Heather A. Parsons, Berry Button, Kelly Kyker-Snowman, Karen Cravero, Bracha Erlanger, Sarah Croessmann, Justin Cidado, Patricia Valda Toro, Hong Yuen Wong, Rory L. Cochran, Daniel J. Zabransky, Dustin A. VanDenBerg, Christina Gersch, Costanza Paoletti, David Chu
Purpose: Mutations in the estrogen receptor (ER)α gene, ESR1, have been identified in breast cancer metastases after progression on endocrine therapies. Because of limitations of metastatic biopsies, the reported frequency of ESR1 mutations may be u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::534a487fe4c889efedb3411fac792aa9
https://doi.org/10.1158/1078-0432.c.6524730.v1
https://doi.org/10.1158/1078-0432.c.6524730.v1
Autor:
Scott A. Tomlins, James M. Rae, Daniel F. Hayes, Ben H. Park, Michael D. Johnson, Farideh Z. Bischoff, Arul M. Chinnaiyan, Dan R. Robinson, Robert Lonigro, Yi-Mi Wu, Anne F. Schott, Christina Gersch, Dafydd G. Thomas, Nahomi Tokudome, Valeria Sero, Allen R. Blevins, Maryam Yazdani, David Chu, Chia-Jen Liu, Paul J. Baratta, Emily M. Cannell, Elizabeth P. Darga, Kimberly Aung, Daniel H. Hovelson, Jose M. Larios, Andi K. Cani, Costanza Paoletti
Supplementary Figure S1. Clinical timelines. Clinical timelines and treatment from first diagnosis until enrollment into MI-CTC-ONCOSEQ for the 11 metastatic breast cancer patients; Supplementary Figure S2. Sanger sequencing of WGA CTC DNA and Wester
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9c2c0c16e842c1ccef93834228e8eef
https://doi.org/10.1158/0008-5472.22420287
https://doi.org/10.1158/0008-5472.22420287
Autor:
Ben Ho Park, James M. Rae, Daniel F. Hayes, Paula J. Hurley, Josh Lauring, Karen S. Jacks, Dan Robinson, Anne Schott, Arul M. Chinnaiyan, Nahomi Tokudome, Kimberly Aung, Arielle Medford, Riaz Gillani, W. Brian Dalton, Heather A. Parsons, Berry Button, Kelly Kyker-Snowman, Karen Cravero, Bracha Erlanger, Sarah Croessmann, Justin Cidado, Patricia Valda Toro, Hong Yuen Wong, Rory L. Cochran, Daniel J. Zabransky, Dustin A. VanDenBerg, Christina Gersch, Costanza Paoletti, David Chu
Supplementary Methods Figure S1 ESR1 Y537SY537N and D538G probes are mutation specific. Figure S2 Patient 1 and Patient 14's plasma DNA. Table S1 Additional patient characteristics. Table S2 Primers used in this study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::855945fa1c6829c1a0e7375846b80ee8
https://doi.org/10.1158/1078-0432.22461237
https://doi.org/10.1158/1078-0432.22461237
Autor:
Eri Takase, Hiroaki Akamatsu, Shunsuke Teraoka, Keita Nakaguchi, Masanori Tanaka, Takahiro Kaki, Katsuyuki Furuta, Koichi Sato, Eriko Murakami, Takeya Sugimoto, Ryota Shibaki, Daichi Fujimoto, Atsushi Hayata, Nahomi Tokudome, Yuichi Ozawa, Yasuhiro Koh, Masanori Nakanishi, Kuninobu Kanai, Toshio Shimokawa, Nobuyuki Yamamoto
Background: The efficacy and tolerability of high-flow nasal cannula (HFNC) for relieving dyspnea in advanced cancer patients with limited prognosis requires elucidation. Methods: Patients with advanced cancer who had dyspnea at rest (numeric rating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::053072e04eee67e8700506ed3cf47b14
https://doi.org/10.21203/rs.3.rs-2639256/v1
https://doi.org/10.21203/rs.3.rs-2639256/v1